DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "US Market Report for Liquid Embolics 2017 - MedCore" report to their offering.
There will be flat growth in the liquid embolics market over the forecast period. The, A Randomized trial of Unruptured Brain Arteriovenous malformations (ARUBA) trial compared interventional and conservative treatment of arteriovenous malformations in the brain. Conservative treatment consisted of a regimen of medication while the intervention arm included embolization. The trial was halted in 2013 due to excessive morbidity associated with the interventional arm.
This outcome slowed growth in terms of unit sales in liquid embolics. Innovation in microcatheters to reduce complications in liquid embolic delivery may slightly increase unit sales. Overall growth in units sold will be flat. The total U.S. liquid embolic market includes TRUFILL n-BCA® from Codman & Shurtleff, Inc and Onyx® from Medtronic. Codman has been on the market for longer and tends to have slightly higher pricing however the ASP will be relatively flat over the projected period.
Key Topics Covered:
Table Of Contents I
List Of Figures Ix
List Of Charts X
U.S. Neuromodulation, Neurovascular, Neurosurgical And Monitoring Device Market Overview
Procedure Codes Investigated
Key Report Updates
St. Jude Medical
Codman & Shurtleff
For more information about this report visit http://www.researchandmarkets.com/research/3zq9vm/us_market_report